Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Special lenses may curb worsening eyesight in children

NCT ID NCT07547072

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Sep 18, 2026 · Updated 3 times

Summary

This study tests two types of modified spectacle lenses designed to slow the progression of myopia (nearsightedness) in children aged 6 to 13. Over one year, researchers will measure changes in the back of the eye (choroid), eye length, and prescription strength. The goal is to see if these lenses can help control myopia without the need for contact lenses or eye drops.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Modified Defocus Incorporated Multiple Segments (DIMS) spectacle lenses
What this could lead to
If successful, these lenses could offer a non-invasive way to slow down worsening nearsightedness in children, reducing the need for stronger prescriptions.
What could go wrong
This is an early study with only 108 participants, so results may not apply to all children. The lenses might not slow myopia as expected, and long-term effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 108 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2026

Expected to finish

Feb 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

6 to 13 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Hong Kong Chinese * Age at enrolment: 6 - 13 years * Myopia in spherical power: -1.00D to -5.00D in both eyes * Astigmatism: equal or less than 2.00D * The sum of spherical power and astigmatism: equal or less than -7.00D * Anisometropia (spherical equivalent refraction (SER)): equal or less than 1.50D * Previous myopia progression (valid documentation dated within 2 years before screening): * -0.50D (SER) per year or more in both eyes OR Axial length elongation: 0.27mm/year in both eyes * If myopia is initially detected during screening, eligibility requires myopia (in SER) below the 3rd percentile curve of refraction in both eyes.12 * Best corrected visual acuity: LogMAR 0.04 or better in both eyes * Ocular health: no abnormalities in both internal and external ocular health * Binocular vision: no strabismus and other binocular abnormalities * Normal colour vision * Willing to wear the study spectacles all the time (10 hours per day, for 7 days per week) Exclusion Criteria: * Previous or current treatment for myopia control (e.g., red-light therapy, atropine, orthokeratology, specialized spectacle lenses and contact lenses and oral supplements for myopic control) * Existing or past eye diseases or surgeries (e.g., strabismus surgery, amblyopia, oculomotor nerve palsies, corneal disease, intraocular disease, etc.) that may have an impact on vision or visual development * Long-term medication (intake at least 3 days/week) or medication/supplements that affect eye health * Systemic diseases that may have an impact on vision or visual development (e.g., endocrine, cardiac and respiratory diseases, diabetes, Down syndrome, etc.) * Allergic to cyclopentolate eye drops * Individuals who, in the judgment of the Investigator, are unable to cooperate and follow instructions during eye examination.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Myopia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Optometry Research Clinic, School of Optometry, The Hong Kong Polytechnic University

    RECRUITING

    Kowloon, Hong Kong, Hong Kong

More trials for these conditions

Other studies related to the condition(s) this trial covers.